Links for 12/22/2016

Another CAR-T Follicular Lymphoma success story, written by Jamie Remo, who is himself a fNHL survivor:

Despite Setbacks, CAR-T Treatment for Cancer Moves Forward
http://www.healthline.com/health-news/car-t-treatment-for-cancer-moves-forward#6


The newest installment in the excellent NY Times series, “Cell Wars: The Science of Immunotherapy“. This article concerns the ethics of price-setting for these expensive therapies, given the public funding that contributed to their success:

Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits – The New York Times


Cytokine Release Syndrome (CRS) remains a significant issue during CAR-T therapy.  I myself spent 5 days in Memorial Sloan-Kettering’s ICU (Intensive Care Unit), 10 days after my CAR-T infusion.  A lot of effort is underway to mitigate this syndrome:

Ruxolitinib may prevent CRS after CAR T-cell therapy (Requires login)
http://www.hematologytimes.com/p_article.do?id=6719


This one is not about CAR-T, but is nonetheless a potential concern for any fNHL patients weighing their “conventional” treatment options. I myself had no issues post-treatment with R-Bendamustine, but I only underwent 4 cycles instead of the usual 6, and did not follow up with Rituxan “maintenance” therapy as mentioned in the article:

Bendamustine Toxicity in FL Raises Eyebrows — and Questions (Requires login)
http://www.medscape.com/viewarticle/873442

 

 

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s